Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) has shared an announcement.
Cambium Bio Limited has notified the ASX of its intention to issue up to 21,276,596 new fully paid ordinary shares under a proposed placement or similar capital-raising structure. The new securities, expected to be issued in mid-June 2026, signal a significant equity raising that may dilute existing shareholders but is likely aimed at strengthening the company’s balance sheet and funding ongoing projects, with potential implications for its market positioning and future growth capacity.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.57 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited, listed on the ASX under the code CMB, operates as a publicly traded company in the biotechnology and life sciences sector. The company raises capital on public markets to support its operations and development activities, using equity placements as a key financing mechanism to fund growth and strategic initiatives.
Average Trading Volume: 8,536
Technical Sentiment Signal: Hold
Current Market Cap: A$13.55M
See more data about CMB stock on TipRanks’ Stock Analysis page.